Combined Application of Nivolumab and Intravesical Bacillus Calmette-Guérin Led to Acute-Onset Type 1 Diabetes

We report a case of acute-onset type 1 diabetes due to combined application of nivolumab and intravesical Bacillus Calmette-Guérin (BCG). An 84-year-old woman underwent lung resection for pulmonary squamous cell carcinoma. She had been treated for type 2 diabetes and later experienced lung cancer re...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiu, Koichi, Fukaya, Yasuo, Kamimoto, Masahiro, Miyamoto, Hideaki, Cong, Yue, Suzuki, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600031/
https://www.ncbi.nlm.nih.gov/pubmed/31275133
http://dx.doi.org/10.1159/000500978
Descripción
Sumario:We report a case of acute-onset type 1 diabetes due to combined application of nivolumab and intravesical Bacillus Calmette-Guérin (BCG). An 84-year-old woman underwent lung resection for pulmonary squamous cell carcinoma. She had been treated for type 2 diabetes and later experienced lung cancer recurrence. She was started on nivolumab treatment, and complete response was achieved for one year. However, during this time, she was diagnosed with superficial bladder cancer and underwent surgery but experienced recurrence. After one month of intravesical BCG instillation, the patient developed acute-onset type 1 diabetes. Thus, we recommend that combined application of nivolumab and intravesical BCG be avoided.

Ejemplares similares